MMCM
AZN icon

Murphy & Mullick Capital Management’s AstraZeneca AZN Stock Holding History

Murphy & Mullick Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403K Sell
2,047
-14
-0.7% -$2.7K 0.3% 78
2025
Q4 		$379K Sell
2,061
-51
-2% -$8.95K 0.27% 81
2025
Q3 		$327K Hold
2,112
– – 0.24% 90
2025
Q2 		$307K Buy
2,112
+125
+6% +$17.5K 0.25% 86
2025
Q1 		$292K Sell
1,987
-43
-2% -$6.22K 0.28% 85
2024
Q4 		$266K Buy
+2,030
New +$284K 0.25% 93

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Murphy & Mullick Capital Management's AZN Position: Q1 2026 in Review

Murphy & Mullick Capital Management reduced its AstraZeneca (AZN) stake by 0.68% in Q1 2026, selling an estimated $2.7K and leaving 2,047 shares worth $403K. The position accounts for 0.3% of the portfolio, ranked #78.

Murphy & Mullick Capital Management first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Murphy & Mullick Capital Management held 2,047 shares of AstraZeneca worth $403K as of Q1 2026.
  • Murphy & Mullick Capital Management sold 14 AstraZeneca shares in Q1 2026, an estimated $2.7K.
  • AstraZeneca made up 0.3% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #78 holding.
  • Murphy & Mullick Capital Management first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.